NCNA
NuCana plc
Price Chart
Latest Quote
$1.12
+0.08 (+7.69%)
Current Price
| Previous Close | $1.04 |
| Open | $1.05 |
| Day High | $1.13 |
| Day Low | $1.03 |
| Volume | 35,251 |
Stock Information
Note: Financial values converted from GBP to USD
| Shares Outstanding | 4.16M |
| Total Debt | $895K |
| Cash Equivalents | $25.96M |
| Net Income | $-12.93M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.66M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-14.35M |
| Income | $-12.93M |
| Book/sh | $6.30 |
| Cash/sh | $4.69 |
| Employees | 10 |
Financial Ratios
| Quick Ratio | 4.56 |
| Current Ratio | 4.73 |
| Debt/Eq | 3.32 |
Returns & Margins
| ROA | -43.49% |
| ROE | -70.26% |
Ownership
| Insider Ownership | 0.00% |
| Institutional Ownership | 2.60% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.12 |
| P/B | 0.18 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.07 |
| SMA50 | $1.27 |
| SMA200 | $1.79 |
| RSI | 47.49 |
| ATR | 0.0594 |
| Shares Float | 4.31M |
| Short Float | 2.40% |
| Short Ratio | 0.53 |
| Volatility | 2.31 |
| Rel Volume | 0.14 |
Performance History
| Week | +11.33% |
| Month | -13.18% |
| Quarter | -7.44% |
| 6 Months | -47.91% |
| YTD | -69.23% |
| Year | -73.71% |
| 3 Years | -99.96% |
| 5 Years | -99.99% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $1.12 | 35,251 |
| 2026-10-26 | $1.04 | 27,100 |
| 2026-10-23 | $0.99 | 27,100 |
| 2026-10-22 | $0.96 | 31,800 |
| 2026-10-21 | $0.96 | 30,100 |
| 2026-10-20 | $1.01 | 29,300 |
| 2026-10-19 | $0.98 | 22,300 |
| 2026-10-16 | $0.99 | 46,700 |
| 2026-10-15 | $1.02 | 55,100 |
| 2026-10-14 | $1.05 | 38,000 |
| 2026-10-13 | $1.05 | 52,000 |
| 2026-10-12 | $1.08 | 28,600 |
| 2026-10-09 | $1.10 | 67,400 |
| 2026-10-08 | $1.13 | 34,600 |
| 2026-10-07 | $1.14 | 51,000 |
| 2026-10-06 | $1.09 | 50,900 |
| 2026-10-05 | $1.06 | 70,300 |
| 2026-10-02 | $1.09 | 320,900 |
| 2026-10-01 | $1.17 | 799,100 |
| 2026-09-30 | $1.35 | 3,304,300 |
| 2026-09-29 | $1.21 | 24,700 |
| 2026-09-28 | $1.29 | 23,600 |
About NuCana plc
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
đ° Latest News
No news articles available at the moment. Check back later for updates on NCNA.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $27,570,007 | $30,444,391 | $41,190,249 | $57,854,269 |
| Other Income Expense | $-13,331,745 | $259,383 | $-2,195,490 | $6,080,938 |
| Other Non Operating Income Expenses | $2,449,579 | - | - | - |
| Net Non Operating Interest Income Expense | $510,825 | $473,771 | $997,830 | $885,342 |
| Operating Expense | $27,570,007 | $30,444,391 | $41,190,249 | $57,854,269 |
| General And Administrative Expense | $10,714,097 | $6,601,027 | $8,023,662 | $9,648,775 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-38,845,217 | $-25,140,278 | $-36,567,678 | $-42,375,999 |
| Net Interest Income | $510,825 | $473,771 | $997,830 | $885,342 |
| Interest Income | $510,825 | $473,771 | $997,830 | $885,342 |
| Normalized Income | $-23,667,824 | $-25,359,756 | $-34,673,648 | $-47,439,784 |
| Net Income From Continuing And Discontinued Operation | $-38,845,217 | $-25,140,278 | $-36,567,678 | $-42,375,999 |
| Total Operating Income As Reported | $-26,613,202 | $-30,185,009 | $-43,385,739 | $-51,773,331 |
| Net Income Common Stockholders | $-38,845,217 | $-25,140,278 | $-36,567,678 | $-42,375,999 |
| Net Income | $-38,845,217 | $-25,140,278 | $-36,567,678 | $-42,375,999 |
| Net Income Including Noncontrolling Interests | $-38,845,217 | $-25,140,278 | $-36,567,678 | $-42,375,999 |
| Net Income Continuous Operations | $-38,845,217 | $-25,140,278 | $-36,567,678 | $-42,375,999 |
| Pretax Income | $-40,390,927 | $-29,711,238 | $-42,387,909 | $-50,887,989 |
| Special Income Charges | $1,112,964 | $-43,672 | $-665,661 | $-386,427 |
| Interest Income Non Operating | $510,825 | $473,771 | $997,830 | $885,342 |
| Operating Income | $-27,570,007 | $-30,444,391 | $-41,190,249 | $-57,854,269 |
| Per Share | ||||
| Diluted EPS | $0.00 | $-1720.40 | $-3506.96 | $-4036.31 |
| Basic EPS | $0.00 | $-1720.40 | $-3506.96 | $-4036.31 |
| Other | ||||
| Tax Effect Of Unusual Items | $-603,931 | $39,905 | $-301,460 | $1,017,153 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,426,076 | $-30,012,969 | $-38,233,815 | $-62,966,492 |
| Total Unusual Items | $-15,781,324 | $259,383 | $-2,195,490 | $6,080,938 |
| Total Unusual Items Excluding Goodwill | $-15,781,324 | $259,383 | $-2,195,490 | $6,080,938 |
| Reconciled Depreciation | $362,607 | $690,805 | $760,944 | $968,715 |
| EBITDA (Bullshit earnings) | $-27,207,400 | $-29,753,586 | $-40,429,305 | $-56,885,554 |
| EBIT | $-27,570,007 | $-30,444,391 | $-41,190,249 | $-57,854,269 |
| Diluted Average Shares | $5,507,875 | $19,636 | $13,915 | $13,825 |
| Basic Average Shares | $5,507,875 | $19,636 | $13,915 | $13,825 |
| Diluted NI Availto Com Stockholders | $-38,845,217 | $-25,140,278 | $-36,567,678 | $-42,375,999 |
| Tax Provision | $-1,545,710 | $-4,570,960 | $-5,820,232 | $-8,511,990 |
| Other Special Charges | $-1,112,964 | - | - | - |
| Impairment Of Capital Assets | $0 | $43,672 | $665,661 | $386,427 |
| Gain On Sale Of Security | $-16,894,288 | $303,054 | $-1,529,829 | $6,467,365 |
| Research And Development | $16,855,910 | $23,843,364 | $33,166,587 | $48,205,495 |
| Selling General And Administration | $10,714,097 | $6,601,027 | $8,023,662 | $9,648,775 |
| Other Gand A | $10,714,097 | $6,601,027 | $8,023,662 | $9,648,775 |
Fetched: 2026-10-11
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $29,285,109 | $4,969,298 | $16,885,025 | $47,823,037 |
| Total Assets | $39,481,764 | $19,551,638 | $36,804,563 | $77,092,266 |
| Total Non Current Assets | $3,934,413 | $3,320,364 | $3,694,881 | $4,412,154 |
| Non Current Deferred Assets | $154,836 | $149,542 | $189,244 | $136,308 |
| Non Current Deferred Taxes Assets | $154,836 | $149,542 | $189,244 | $136,308 |
| Goodwill And Other Intangible Assets | $2,908,793 | $2,910,116 | $2,816,156 | $3,129,797 |
| Other Intangible Assets | $2,908,793 | $2,910,116 | $2,816,156 | $3,129,797 |
| Current Assets | $35,547,350 | $16,231,274 | $33,109,682 | $72,680,112 |
| Prepaid Assets | $987,243 | $1,160,606 | $2,605,738 | $4,375,099 |
| Receivables | $2,466,783 | $6,139,167 | $7,708,697 | $9,287,491 |
| Other Receivables | $54,259 | $31,761 | $51,612 | $66,169 |
| Taxes Receivable | $2,412,524 | $6,107,406 | $7,657,085 | $9,221,322 |
| Cash Cash Equivalents And Short Term Investments | $32,093,325 | $8,931,502 | $22,795,246 | $55,465,565 |
| Cash And Cash Equivalents | $32,093,325 | $8,931,502 | $22,795,246 | $55,465,565 |
| Cash Financial | $32,093,325 | $8,931,502 | $22,795,246 | $55,465,565 |
| Other Current Assets | - | - | - | $3,551,956 |
| Other Non Current Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $894,606 | $251,442 | $524,059 | $845,641 |
| Long Term Debt And Capital Lease Obligation | $868,138 | $154,836 | $251,442 | $524,059 |
| Current Debt And Capital Lease Obligation | $26,468 | $96,607 | $272,617 | $321,582 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $7,287,862 | $11,672,225 | $17,103,383 | $26,139,431 |
| Total Non Current Liabilities Net Minority Interest | $944,894 | $203,801 | $328,199 | $584,935 |
| Current Liabilities | $6,342,968 | $11,468,424 | $16,775,184 | $25,554,497 |
| Payables And Accrued Expenses | $6,316,500 | $11,318,882 | $16,502,567 | $19,807,051 |
| Payables | $821,820 | $3,757,080 | $4,671,537 | $6,570,589 |
| Total Tax Payable | $131,015 | $177,333 | $205,124 | $214,388 |
| Accounts Payable | $690,805 | $3,579,747 | $4,466,413 | $6,356,201 |
| Equity | ||||
| Common Stock Equity | $32,193,902 | $7,879,413 | $19,701,180 | $50,952,835 |
| Total Equity Gross Minority Interest | $32,193,902 | $7,879,413 | $19,701,180 | $50,952,835 |
| Stockholders Equity | $32,193,902 | $7,879,413 | $19,701,180 | $50,952,835 |
| Gains Losses Not Affecting Retained Earnings | $115,233,444 | $103,780,901 | $104,776,083 | $100,407,601 |
| Other Equity Adjustments | $115,233,444 | $103,780,901 | $104,776,083 | $100,407,601 |
| Retained Earnings | $-333,934,147 | $-296,826,530 | $-274,874,278 | $-238,966,968 |
| Other | ||||
| Treasury Shares Number | $661,691 | $661,691 | $661,691 | $661,691 |
| Ordinary Shares Number | $27,539,377,055 | $187,307,711 | $69,292,699 | $68,647,619 |
| Share Issued | $27,540,038,745 | $187,969,401 | $69,954,389 | $69,309,310 |
| Tangible Book Value | $29,285,109 | $4,969,298 | $16,885,025 | $47,823,037 |
| Invested Capital | $32,193,902 | $7,879,413 | $19,701,180 | $50,952,835 |
| Working Capital | $29,204,383 | $4,762,850 | $16,334,498 | $47,125,615 |
| Capital Lease Obligations | $894,606 | $251,442 | $524,059 | $845,641 |
| Total Capitalization | $32,193,902 | $7,879,413 | $19,701,180 | $50,952,835 |
| Additional Paid In Capital | $231,917,314 | $193,406,913 | $187,001,746 | $186,739,717 |
| Capital Stock | $18,977,291 | $7,518,130 | $2,797,628 | $2,772,484 |
| Common Stock | $18,977,291 | $7,518,130 | $2,797,628 | $2,772,484 |
| Long Term Capital Lease Obligation | $868,138 | $154,836 | $251,442 | $524,059 |
| Long Term Provisions | $76,756 | $48,965 | $76,756 | $60,876 |
| Current Capital Lease Obligation | $26,468 | $96,607 | $272,617 | $321,582 |
| Current Accrued Expenses | $5,494,680 | $7,561,802 | $11,831,031 | $13,236,462 |
| Net PPE | $870,785 | $260,706 | $689,482 | $1,146,048 |
| Accumulated Depreciation | $-1,341,909 | $-1,237,362 | $-2,345,032 | $-1,893,759 |
| Gross PPE | $2,212,694 | $1,498,068 | $3,034,514 | $3,039,807 |
| Other Properties | $1,447,779 | $759,621 | $1,770,684 | $1,794,505 |
| Machinery Furniture Equipment | $764,915 | $738,447 | $1,263,829 | $1,245,302 |
| Current Provisions | - | $52,935 | - | $5,425,864 |
Fetched: 2026-10-11
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,137,102 | $-25,688,158 | $-35,621,460 | $-31,332,380 |
| Operating Activities | ||||
| Operating Cash Flow | $-9,881,690 | $-25,300,408 | $-34,988,883 | $-30,646,869 |
| Cash Flow From Continuing Operating Activities | $-9,881,690 | $-25,300,408 | $-34,988,883 | $-30,646,869 |
| Operating Gains Losses | $256,736 | $-488,328 | $1,556,297 | $-6,635,435 |
| Investing Activities | ||||
| Capital Expenditure | $-255,413 | $-387,751 | $-632,576 | $-685,512 |
| Investing Cash Flow | $210,418 | $104,547 | $3,821,926 | $158,806 |
| Cash Flow From Continuing Investing Activities | $210,418 | $104,547 | $3,821,926 | $158,806 |
| Net Other Investing Changes | - | - | $3,435,498 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $26,712,456 | $11,551,797 | $329,522 | $0 |
| Financing Cash Flow | $33,092,478 | $10,830,554 | $-70,139 | $-213,064 |
| Cash Flow From Continuing Financing Activities | $33,092,478 | $10,830,554 | $-70,139 | $-213,064 |
| Net Other Financing Charges | $-1,781,271 | $-435,393 | $-47,642 | - |
| Net Common Stock Issuance | $26,712,456 | $11,551,797 | $329,522 | $0 |
| Common Stock Issuance | $26,712,456 | $11,551,797 | $329,522 | $0 |
| Other | ||||
| Repayment Of Debt | $-71,463 | $-295,114 | $-357,313 | $-300,408 |
| End Cash Position | $32,093,325 | $8,931,502 | $22,795,246 | $55,465,565 |
| Beginning Cash Position | $8,931,502 | $22,795,246 | $55,465,565 | $79,752,263 |
| Effect Of Exchange Rate Changes | $-259,383 | $501,562 | $-1,433,222 | $6,414,430 |
| Changes In Cash | $23,421,206 | $-14,365,306 | $-31,237,097 | $-30,701,127 |
| Proceeds From Stock Option Exercised | $8,232,756 | $9,264 | $5,294 | $87,343 |
| Net Issuance Payments Of Debt | $-71,463 | $-295,114 | $-357,313 | $-300,408 |
| Net Long Term Debt Issuance | $-71,463 | $-295,114 | $-357,313 | $-300,408 |
| Long Term Debt Payments | $-71,463 | $-295,114 | $-357,313 | $-300,408 |
| Interest Received Cfi | $465,830 | $492,298 | $1,019,004 | $844,317 |
| Net Intangibles Purchase And Sale | $-255,413 | $-382,457 | $-627,283 | $-669,631 |
| Purchase Of Intangibles | $-255,413 | $-382,457 | $-627,283 | $-669,631 |
| Net PPE Purchase And Sale | $0 | $-5,294 | $-5,294 | $-15,881 |
| Purchase Of PPE | $0 | $-5,294 | $-5,294 | $-15,881 |
| Taxes Refund Paid | $5,277,645 | $5,313,377 | $7,404,319 | $9,554,814 |
| Change In Working Capital | $-4,859,457 | $-2,888,942 | $-1,695,252 | $4,926,949 |
| Change In Payables And Accrued Expense | $-5,003,705 | $-5,187,655 | $-3,328,304 | $4,520,671 |
| Change In Payable | $-5,003,705 | $-5,187,655 | $-3,328,304 | $4,520,671 |
| Change In Account Payable | $-2,888,942 | $-886,666 | $-1,889,789 | $3,935,737 |
| Change In Tax Payable | $-2,114,764 | $-4,300,990 | $-1,438,516 | $584,935 |
| Change In Income Tax Payable | $-2,114,764 | $-4,300,990 | $-1,438,516 | $584,935 |
| Change In Prepaid Assets | $144,249 | $2,298,714 | $1,633,053 | $406,278 |
| Other Non Cash Items | $16,253,772 | $-451,273 | $-959,452 | $-857,551 |
| Stock Based Compensation | $13,270,870 | $2,178,286 | $5,104,282 | $6,471,336 |
| Provisionand Write Offof Assets | $-52,935 | $13,234 | $-5,437,775 | $5,425,864 |
| Asset Impairment Charge | $0 | $43,672 | $665,661 | $386,427 |
| Deferred Tax | $-1,545,710 | $-4,570,960 | $-5,820,232 | $-8,511,990 |
| Deferred Income Tax | $-1,545,710 | $-4,570,960 | $-5,820,232 | $-8,511,990 |
| Depreciation Amortization Depletion | $362,607 | $690,805 | $760,944 | $968,715 |
| Depreciation And Amortization | $362,607 | $690,805 | $760,944 | $968,715 |
| Amortization Cash Flow | $258,059 | $244,826 | $275,263 | $968,715 |
| Amortization Of Intangibles | $258,059 | $244,826 | $275,263 | $968,715 |
| Depreciation | $104,547 | $445,980 | $485,681 | - |
| Net Foreign Currency Exchange Gain Loss | $256,736 | $-488,328 | $1,556,297 | $-6,635,435 |
| Net Income From Continuing Operations | $-38,845,217 | $-25,140,278 | $-36,567,678 | $-42,375,999 |
Fetched: 2026-10-11